William DuVal

Cooley advised Sword Health, pioneer of the AI Care platform, which uses artificial intelligence to power the delivery of care, on its raise of $130 million in a mix of primary and secondary sales.

Cooley advised Autolus – a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies – on its strategic collaboration with BioNTech, an immunotherapy company pioneering novel therapies for cancer and other serious diseases, to advance both companies’ autologous CAR-T programs toward commercialization, as well as a $350 million underwritten offering.

Cooley advised Luna Innovations, a global leader in advanced fiber optic-based technology, on its $50 million investment from White Hat Capital Partners and its acquisition of Silixa.

Cooley advised Cardlytics, an advertising platform in banks’ digital channels, on its cooperation agreement with CAS Investment Partners, a 14.4% stockholder of Cardlytics.

Cooley advised the underwriters on Nanobiotix’s $113.3 million initial public offering of 8,395,000 ordinary shares (global offering) – including the offering of 6,540,000 American depositary shares, each representing one ordinary share, in the US (the US offering) and a concurrent offering of 1,855,000 ordinary shares in certain jurisdictions outside of the US to certain investors (the European offering) – which includes the full exercise of the underwriters’ option to purchase additional shares. Jefferies acted as global coordinator and joint book-running manager for the global offering; Evercore Group and UBS Securities acted as joint book-running managers for the US offering; and Gilbert Dupont acted as manager for the European offering. Nanobiotix, whose securities now trade on the Nasdaq Global Select Market under the symbol NBTX, also trades on the Euronext Paris Market under the symbol NANO. Nanobiotix is a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancers. Partners Brian Leaf, Div Gupta and David Boles led the Cooley team.